-
公开(公告)号：US20240360120A1
公开(公告)日：2024-10-31
申请号：US18427164
申请日：2024-01-30
IPC分类号： C07D417/14 , C07D277/30 , C07D417/12 , C07D471/04
CPC分类号： C07D417/14 , C07D277/30 , C07D417/12 , C07D471/04
摘要： This application is directed to inhibitors of RAD51 represented by the following structural formula,
and methods for their use, such as to treat cancer, autoimmune diseases, immune deficiencies, or neurodegenerative diseases.-
公开(公告)号：US20240360116A1
公开(公告)日：2024-10-31
申请号：US18255134
申请日：2021-12-03
IPC分类号： C07D413/14 , A61K31/4709 , A61K31/538 , A61K31/541 , A61K31/69 , A61P33/10 , C07D265/36 , C07D413/12 , C07D417/14 , C07D471/04 , C07D491/107 , C07F5/02
CPC分类号： C07D413/14 , A61K31/4709 , A61K31/538 , A61K31/541 , A61K31/69 , A61P33/10 , C07D265/36 , C07D413/12 , C07D417/14 , C07D471/04 , C07D491/107 , C07F5/02
摘要： The present invention provides compounds of formula (I′):
which are useful in the control of endoparasites, for example heartworms, in warm-blooded animals.-
公开(公告)号：US12129243B2
公开(公告)日：2024-10-29
申请号：US18513400
申请日：2023-11-17
发明人： Marion Lanier , Marcus Boehm , Liming Huang , Esther Martinborough , Marcos Sainz , Brandon Selfridge , Adam Yeager
IPC分类号： C07D471/04 , C07D401/12 , C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D498/04
CPC分类号： C07D401/12 , C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D498/04
摘要： Methods are provided for modulating MRGPRX2 generally, or for treating a MRGPRX2 or a MRGPRX2 ortholog dependent condition, more specifically, by contacting the MRGPRX2 or the MRGPRX2 ortholog by administering to a subject in need thereof, respectively, an effective amount of a compound having structure (I):
or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, wherein W, Z, R1, R2, R3, R4, R5, R6 and Rx are as defined herein. Pharmaceutical compositions containing such compounds, as well as the compounds themselves, are also provided.-
4.发明公开公开(公告)号：US20240351988A1
公开(公告)日：2024-10-24
申请号：US18685378
申请日：2022-09-14
发明人： Jinshan Chen , Rajiv Chopra , Jiamin Gu
IPC分类号： C07D237/24 , A61K31/496 , A61K31/50 , A61K31/501 , A61K31/506 , A61K31/517 , A61K31/519 , A61K31/55 , A61K31/551 , A61K39/395 , A61P35/00 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D413/14 , C07D417/14 , C07D471/04
CPC分类号： C07D237/24 , A61K31/496 , A61K31/50 , A61K31/501 , A61K31/506 , A61K31/517 , A61K31/519 , A61K31/55 , A61K31/551 , A61K39/3955 , A61P35/00 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D413/14 , C07D417/14 , C07D471/04
摘要： Disclosed herein are compounds which can act modulators of the aryl hydrocarbon receptor (AHR). Further disclosed herein are methods for treating diseases and disorders, such as cancer and viral infections, using the compounds disclosed herein.
-
公开(公告)号：US20240343727A1
公开(公告)日：2024-10-17
申请号：US18578677
申请日：2022-08-16
发明人： Xianhai HUANG , Younong YU , Haotao NIU , Hong YANG , Shanshan WANG , Jifang WENG , Yaolin WANG , Xing DAI
IPC分类号： C07D471/04 , A61K31/501 , A61K31/502 , A61K31/5025 , A61K31/506 , A61K31/5377 , A61P35/00 , C07D401/14 , C07D403/14 , C07D413/14 , C07D417/14 , C07D487/04 , C07D487/10 , C07D491/052 , C07D491/107
CPC分类号： C07D471/04 , A61K31/501 , A61K31/502 , A61K31/5025 , A61K31/506 , A61K31/5377 , A61P35/00 , C07D401/14 , C07D403/14 , C07D413/14 , C07D417/14 , C07D487/04 , C07D487/10 , C07D491/052 , C07D491/107
摘要： Provided herein are novel compounds, for example, compounds having a Formula (I), or a pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the same. Also provided herein are methods of preparing the compounds and methods of using the compounds, for example, in treating cancer.
-
公开(公告)号：US20240343718A1
公开(公告)日：2024-10-17
申请号：US18526732
申请日：2023-12-01
申请人： TORQUR AG , UNIVERSITÄT BASEL
发明人： Denise RAGEOT , Paul HEBEISEN , Florent BEAUFILS , Doriano FABBRO , Petra HILLMAN-WULLNER , Hoa Huu Phuc NGUYEN , Wolfgang LOSCHER , Claudia BRANDT , Alexander Markus SELE
IPC分类号： C07D413/14 , A61K31/53 , A61K31/5377 , A61K31/5386 , A61K31/541 , A61P25/08 , A61P25/28 , C07D417/14 , C07D451/02 , C07D451/14 , C07D498/08 , C07D519/00
CPC分类号： C07D413/14 , A61K31/53 , A61K31/5377 , A61K31/5386 , A61K31/541 , A61P25/08 , A61P25/28 , C07D417/14 , C07D451/02 , C07D451/14 , C07D498/08 , C07D519/00
摘要： The present invention is relates to a compound of formula (I), wherein X1, X2 and X3 are, independently of each other, N or CH; with the proviso that at least two of X1X2 and X3 are N; Y is N or CH; R1 and R2 are independently of each other (iii) a morpholinyl of formula (II) wherein the arrow denotes the bond in formula (I); and wherein R3 and R4 are independently of each other H, C1-C3alkyl optionally substituted with one or two OH, C1-C2fhioroalkyl, C1-C2alkoxy, C1-C2alkoxyC1-C3alkyl, CN, or C(0)0-C1-C2alkyl; or R3 and R4 form together a bivalent residue —R5R6- selected from Ci-C3alkylene optionally substituted with 1 to 4 F, —CH2-0-CH2—, —CH2—NH—CH2—, or any of the structures wherein the arrows denote the bonds in formula (II); or (iv) a saturated 6-membered heterocyclic ring Z selected from thiomorpholinyl and piperazinyl, optionally substituted by 1 to 3 R7; wherein R7 is independently at each occurrence Ci-C3alkyl optionally substituted with one or two OH, C1-C2fluoroalkyl, C1-C2alkoxyC1-C3 alkyl, C3-C6cycloalkyl; or two R7 substituents form together a bivalent residue —R8R9— selected from C1-C3alkylene optionally substituted with 1 to 4 F, —CH2-0-CH2— or —O—CH2CH2-0-; with the proviso that at least one of R1 and R2 is a morpholinyl of formula II; and prodrugs, metabolites, tautomers, solvates and pharmaceutically acceptable salts thereof, for use in the prevention or treatment of a neurological disorder in a subject.
-
公开(公告)号：US20240343717A1
公开(公告)日：2024-10-17
申请号：US18294191
申请日：2022-07-28
发明人： Andrew EDMUNDS , Christopher Charles SCARBOROUGH , Simon WILLIAMS , Pierre Joseph Marcel JUNG , Peter FINKBEINER , Martin POULIOT , Daria GROSHEVA , Lars SUESSE , Guillaume BRUNOT , Damien BONVALOT
IPC分类号： C07D413/14 , A01N43/80 , A01N43/82 , A01P3/00 , C07D401/06 , C07D403/06 , C07D417/14
CPC分类号： C07D413/14 , A01N43/80 , A01N43/82 , A01P3/00 , C07D401/06 , C07D403/06 , C07D417/14
摘要： A compound of formula (I) wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, which can be used as fungicides.
-
公开(公告)号：US12116358B2
公开(公告)日：2024-10-15
申请号：US17268151
申请日：2019-08-14
申请人： EPIZYME, INC.
发明人： John Lampe , John Campbell , Kenneth Duncan , Megan Alene Cloonan Foley , Darren Martin Harvey , Michael John Munchhof , Michael Thomenius , Lawrence Alan Reiter
IPC分类号： C07D403/12 , A61P35/00 , C07D209/42 , C07D209/96 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D471/04 , C07D471/08 , C07D471/10 , C07D487/04 , C07D487/08 , C07D487/10 , C07D491/08 , C07D491/107 , C07D498/04 , C07D498/08 , C07D498/10 , C07D513/10
CPC分类号： C07D403/12 , A61P35/00 , C07D209/42 , C07D209/96 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D471/04 , C07D471/08 , C07D471/10 , C07D487/04 , C07D487/08 , C07D487/10 , C07D491/08 , C07D491/107 , C07D498/04 , C07D498/08 , C07D498/10 , C07D513/10
摘要： Compounds of Formula I: (I) and the pharmaceutically acceptable salts and solvates thereof, wherein R1a, R1e, G1, G2, Q1, Q2, Q3, and (II) are defined as set forth in the specification, as are uses of compounds of Formula I to treat a disease, disorder, or condition such as cancer in a subject.
-
公开(公告)号：US20240336609A1
公开(公告)日：2024-10-10
申请号：US18666699
申请日：2024-05-16
IPC分类号： C07D417/14 , A61K31/4439 , A61K31/444 , A61K31/501 , A61K31/5377 , C07D417/04
CPC分类号： C07D417/14 , A61K31/4439 , A61K31/444 , A61K31/501 , A61K31/5377 , C07D417/04
摘要： Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-α.
-
公开(公告)号：US20240336608A1
公开(公告)日：2024-10-10
申请号：US18617907
申请日：2024-03-27
发明人： David A. Candito , Anthony Donofrio , Ronald Dale Ferguson, II , George Madalin Giambasu , Anmol Gulati , Andrew M. Haidle , Brett A. Hopkins , William P. Kaplan , Ping Liu , Michaelyn C. Lux , Xiao Mei Zheng , Ryan D. Otte , Alexander Pasternak , Elsie C. Yu
IPC分类号： C07D417/14 , A61K31/422 , A61K31/433 , A61K31/437 , A61K31/4439 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/542 , A61K39/395 , C07D401/14 , C07D403/12 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D471/04 , C07D487/04 , C07D491/048 , C07D495/04 , C07D513/04
CPC分类号： C07D417/14 , A61K31/422 , A61K31/433 , A61K31/437 , A61K31/4439 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/542 , A61K39/3955 , C07D401/14 , C07D403/12 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D471/04 , C07D487/04 , C07D491/048 , C07D495/04 , C07D513/04
摘要： Described herein are compounds of Formula I
or a pharmaceutically acceptable salt thereof, wherein R1, R2, A, and B are as defined herein. The compounds of Formula I act as IL4I1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for IL4I1-related diseases.
-
-
-
-
-
-
-
-
-
搜索结果
11064 条记录 (耗时 0.038 秒)
